Translational Preclinical PET Imaging and Metabolic Evaluation of a New Cannabinoid 2 Receptor (CB<sub>2</sub>R) Radioligand, (<i>Z</i>)-<i>N</i>-(3-(2-(2-[<sup>18</sup>F]Fluoroethoxy)ethyl)-4,5-dimethylthiazol-2(3<i>H</i>)-ylidene)-2,2,3,3-tetrameth

We have previously developed seven fluorinated analogues of A-836339 as new PET tracers for cannabinoid type 2 receptor (CB<sub>2</sub>R) imaging, among which (<i>Z</i>)-<i>N</i>-(3-(2-(2-[<sup>18</sup>F]fluoroethoxy)ethyl)-4,5-dimethylthiazol-2(3<i>H</i>)-ylidene)-2,2,3,3-tetramethylcyclopropane-1-carboxamide ([<sup>18</sup>F]FC0324) displayed high affinity and selectivity for CB<sub>2</sub>R in healthy rats. In the present study, we have further evaluated the imaging and metabolic properties of [<sup>18</sup>F]FC0324 in a rat model of human CB<sub>2</sub>R overexpression in the brain (AAV-<i>h</i>CB<sub>2</sub>) and in non-human primates (NHPs). Autoradiography with AAV-<i>h</i>CB<sub>2</sub> rat brain sections exhibited a signal of [<sup>18</sup>F]FC0324 8-fold higher in the ipsilateral region than in the contralateral region. Blocking with NE40, a CB<sub>2</sub>R-specific agonist, resulted in a 91% decrease in the radioactivity. PET experiments showed a signal 7-fold higher in the ipsilateral region, and the specificity of [<sup>18</sup>F]FC0324 for <i>h</i>CB<sub>2</sub>R in vivo was confirmed by the 80% decrease after blocking with NE40. In NHPs, brain time-activity curves displayed a fast and homogeneous distribution followed by a rapid washout, in accordance with the low amount of CB<sub>2</sub>Rs in healthy brain. Whole-body PET-CT suggested a high and specific uptake of the radiotracer in the spleen, a CB<sub>2</sub>R-rich organ, and in the organs involved in metabolism and excretion, with a low bone uptake. In vitro metabolism with monkey liver microsomes (MLMs) led to the formation of six main hydroxylated metabolites of FC0324. Five of them were produced by human liver microsomes, being much less active than MLMs. In vivo, in NHPs, the main radiometabolite was likely to result from further oxidation of hydroxylated compounds, and parent [<sup>18</sup>F]FC0324 accounted for 8 ± 3% of plasma radioactivity (at 120 min p.i.) with a low level of potential interfering radiometabolites. Furthermore, this metabolism should be significantly reduced in humans due to species differences. In conclusion, [<sup>18</sup>F]FC0324 appears to be a promising candidate for further human studies with suitable kinetics, selectivity, and metabolic profile for CB<sub>2</sub>R PET imaging.

Authors

Institutions

Publication Details

Journal
ACS Pharmacology & Translational Science
Published
2024-09-13
DOI
https://doi.org/10.1021/acsptsci.4c00348
Citations
5
Primary Topic
Cannabis and Cannabinoid Research
Type
article
Field-Weighted Citation Impact
2.24
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Translational Preclinical PET Imaging and Metabolic Evaluation of a New Cannabinoid 2 Receptor (CB2R) Radioligand, (Z)-N-(3-(2-(2-[18F]Fluoroethoxy)ethyl)-4,5-dimethylthiazol-2(3H)-ylidene)-2,2,3,3-tetrameth

Jérôme Cayla, Michel Bottlaender, Claire Leroy, Sylvain Auvity et al.
5 citations
ACS Pharmacology & Translational Science
Cannabis and Cannabinoid Research
2.24
article

Translational Preclinical PET Imaging and Metabolic Evaluation of a New Cannabinoid 2 Receptor (CB2R) Radioligand, (Z)-N-(3-(2-(2-[18F]Fluoroethoxy)ethyl)-4,5-dimethylthiazol-2(3H)-ylidene)-2,2,3,3-tetrameth

Jérôme Cayla, Michel Bottlaender, Claire Leroy, Sylvain Auvity, Bertrand Kühnast, Stéphane Demphel, Bala Attili, Guy Bormans, Vincent Brulon, Fabien Caillé, Maud Goislard, Marie‐Anne Peyronneau, Françoise Hinnen
article en
5 citations

Abstract

We have previously developed seven fluorinated analogues of A-836339 as new PET tracers for cannabinoid type 2 receptor (CB<sub>2</sub>R) imaging, among which (<i>Z</i>)-<i>N</i>-(3-(2-(2-[<sup>18</sup>F]fluoroethoxy)ethyl)-4,5-dimethylthiazol-2(3<i>H</i>)-ylidene)-2,2,3,3-tetramethylcyclopropane-1-carboxamide ([<sup>18</sup>F]FC0324) displayed high affinity and selectivity for CB<sub>2</sub>R in healthy rats. In the present study, we have further evaluated the imaging and metabolic properties of [<sup>18</sup>F]FC0324 in a rat model of human CB<sub>2</sub>R overexpression in the brain (AAV-<i>h</i>CB<sub>2</sub>) and in non-human primates (NHPs). Autoradiography with AAV-<i>h</i>CB<sub>2</sub> rat brain sections exhibited a signal of [<sup>18</sup>F]FC0324 8-fold higher in the ipsilateral region than in the contralateral region. Blocking with NE40, a CB<sub>2</sub>R-specific agonist, resulted in a 91% decrease in the radioactivity. PET experiments showed a signal 7-fold higher in the ipsilateral region, and the specificity of [<sup>18</sup>F]FC0324 for <i>h</i>CB<sub>2</sub>R in vivo was confirmed by the 80% decrease after blocking with NE40. In NHPs, brain time-activity curves displayed a fast and homogeneous distribution followed by a rapid washout, in accordance with the low amount of CB<sub>2</sub>Rs in healthy brain. Whole-body PET-CT suggested a high and specific uptake of the radiotracer in the spleen, a CB<sub>2</sub>R-rich organ, and in the organs involved in metabolism and excretion, with a low bone uptake. In vitro metabolism with monkey liver microsomes (MLMs) led to the formation of six main hydroxylated metabolites of FC0324. Five of them were produced by human liver microsomes, being much less active than MLMs. In vivo, in NHPs, the main radiometabolite was likely to result from further oxidation of hydroxylated compounds, and parent [<sup>18</sup>F]FC0324 accounted for 8 ± 3% of plasma radioactivity (at 120 min p.i.) with a low level of potential interfering radiometabolites. Furthermore, this metabolism should be significantly reduced in humans due to species differences. In conclusion, [<sup>18</sup>F]FC0324 appears to be a promising candidate for further human studies with suitable kinetics, selectivity, and metabolic profile for CB<sub>2</sub>R PET imaging.

ACS Pharmacology & Translational ScienceVol. 7(10)
Hôpital Necker-Enfants Malades (FR), Centre National de la Recherche Scientifique (FR), Inserm (FR), Université Paris Cité (FR), Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR), Université Paris-Saclay (FR), Institut d'Imagerie Biomédicale (FR), Sorbonne Paris Cité (FR), Assistance Publique – Hôpitaux de Paris (FR), CEA Paris-Saclay (FR), KU Leuven (BE)
Openalex Percentile: Top 12%
Cannabis and Cannabinoid Research
2.24
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.